Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia
| Autor: | Kamlesh Khunti, Samuel Seidu, Sachin Khunti |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
insulin Endocrinology Diabetes and Metabolism media_common.quotation_subject Treatment intensification prevalence Therapeutic inertia Type 2 diabetes Review Inertia lcsh:Diseases of the endocrine glands. Clinical endocrinology system level medicine System level Intensive care medicine media_common lcsh:RC648-665 Health professionals business.industry causes providers medicine.disease patient level oral antihyperglycaemic drugs type 2 diabetes business Healthcare system |
| Zdroj: | Therapeutic Advances in Endocrinology and Metabolism, Vol 10 (2019) Therapeutic Advances in Endocrinology and Metabolism |
| ISSN: | 2042-0196 |
| Popis: | Early glycaemic control leads to better outcomes, including a reduction in long-term macrovascular and microvascular complications. Despite good-quality evidence, glycaemic control has been shown to be inadequate globally. Therapeutic inertia has been shown present in all stages of treatment intensification, from the first oral antihyperglycaemic drug (OAD), all the way to the initiation of insulin. The causes and possible solutions to the problem of therapeutic inertia are complex but can be understood better when viewed from the perspective of the providers [healthcare professionals (HCPs)], patients and healthcare systems. In this review, we will discuss the possible aetiologies, consequences and solutions of therapeutic inertia, drawing upon evidence from published literature on the subject of type 2 diabetes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|